Goldman Sachs analyst maintained a Buy rating on Santen Pharmaceutical Co today and set a price target of Yen2,200.00. The company’s shares closed last Wednesday at $11.45.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
In addition to Goldman Sachs, Santen Pharmaceutical Co also received a Buy from TR | OpenAI – 4o’s Veda Pharmyne in a report issued on October 3. However, on October 8, TR | OpenAI – 4o downgraded Santen Pharmaceutical Co (Other OTC: SNPHF) to a Hold.
SNPHF market cap is currently $3.53B and has a P/E ratio of 16.99.
Read More on SNPHF:
Disclaimer & DisclosureReport an Issue
- Santen Pharmaceutical Announces Disposal of Treasury Shares for Stock Remuneration Plan
- Santen Pharmaceutical Reports Progress on Share Buyback Initiative
- Santen Pharmaceutical Suspends Treasury Share Disposal Plan
- Santen Pharmaceutical Announces Treasury Share Disposal for Performance-linked Remuneration
- Santen Pharmaceutical Updates on Share Buyback Progress
This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
/Blackrock%20Inc_%20logo%20on%20building-%20by%20Tada%20Images%20via%20Shutterstock.jpg)
/NVIDIA%20Corp%20logo%20on%20phone-by%20Evolf%20via%20Shutterstock.jpg)
/Micron%20Technology%20Inc_%20logo%20on%20building-by%20vzphotos%20vis%20iStock.jpg)
/A%20Palantir%20office%20building%20in%20Tokyo_%20Image%20by%20Hiroshi-Mori-Stock%20via%20Shutterstock_.jpg)
/Semiconductor%20chip%20by%20Mykola%20Pokhodzhay%20via%20iStock.jpg)